JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB260046

Anti-LOXL2 antibody [EPR23035-105]

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Recombinant Monoclonal LOXL2 antibody. Suitable for IP, WB and reacts with Human samples.

View Alternative Names

Lysyl oxidase homolog 2, Lysyl oxidase-like protein 2, Lysyl oxidase-related protein 2, Lysyl oxidase-related protein WS9-14, LOXL2

3 Images
Immunoprecipitation - Anti-LOXL2 antibody [EPR23035-105] (AB260046)
  • IP

Unknown

Immunoprecipitation - Anti-LOXL2 antibody [EPR23035-105] (AB260046)

LOXL2 was immunoprecipitated from 0.35 mg MDA-MB-435S (Human mammary gland ductal carcinoma melanocyte) whole cell lysate with ab260046 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab260046 at 1/500 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366) was used at 1/1000 dilution.

Lane 1 : MDA-MB-435S (Human mammary gland ductal carcinoma melanocyte) whole cell lysate 10ug

Lane 2 : ab260046 IP in MDA-MB-435S whole cell lysate

Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab260046 in MDA-MB-435S whole cell lysate

Blocking and dilution buffer and concentration : 5% NFDM/TBST.

Exposure time : 3 minutes.

LOXL2 is a glycoprotein. Unprocessed LOXL2 (100kDa) and processed LOXL2(70kDa) are observed. The molecular weight observed is consistent with what has been described in the literature (PMID : 27770022).

All lanes:

Immunoprecipitation - Anti-LOXL2 antibody [EPR23035-105] (ab260046)

Predicted band size: 87 kDa

Observed band size: 100 kDa,70 kDa

false

Western blot - Anti-LOXL2 antibody [EPR23035-105] (AB260046)
  • WB

Unknown

Western blot - Anti-LOXL2 antibody [EPR23035-105] (AB260046)

Blocking and dilution buffer : 5% NFDM/TBST.

LOXL2 is a glycoprotein. Unprocessed LOXL2 (100kDa) and processed LOXL2(70kDa) are observed.

The molecular weight observed is consistent with what has been described in the literature (PMID : 27770022).

Negative control : MCF7 (PMID : 12154058).

All lanes:

Western blot - Anti-LOXL2 antibody [EPR23035-105] (ab260046) at 1/1000 dilution

Lane 1:

MDA-MB-435S (human mammary gland ductal carcinoma melanocyte) whole cell lysate at 20 µg

Lane 2:

MDA-MB-231 (human breast adenocarcinoma epithelial cell) whole cell lysate at 20 µg

Lane 3:

U-87 MG (human glioblastoma-astrocytoma epithelial cell) whole cell lysate at 20 µg

Lane 4:

MCF7 (human breast adenocarcinoma epithelial cell) whole cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Predicted band size: 87 kDa

Observed band size: 100 kDa,70 kDa

false

Exposure time: 48s

Western blot - Anti-LOXL2 antibody [EPR23035-105] (AB260046)
  • WB

Unknown

Western blot - Anti-LOXL2 antibody [EPR23035-105] (AB260046)

Blocking and dilution buffer : 5% NFDM/TBST.

LOXL2 is a glycoprotein. Unprocessed LOXL2 (100kDa) and processed LOXL2(70kDa) are observed.

The expression of LOXL2 is elevated under hypoxia condition.

The expression profile and molecular weight observed is consistent with what has been described in the literature (PMID : 20026874; PMID : 27770022).

All lanes:

Western blot - Anti-LOXL2 antibody [EPR23035-105] (ab260046) at 1/1000 dilution

Lane 1:

Untreated HeLa (human cervix adenocarcinoma epithelial cell), whole cell lysate at 20 µg

Lane 2:

HeLa treated with 2mM Deferoxamine mesylate (DFO) for 24 hours, whole cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Predicted band size: 87 kDa

Observed band size: 100 kDa,70 kDa

false

Exposure time: 3min

  • Carrier free

    Anti-LOXL2 antibody [EPR23035-105] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR23035-105

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

WB, IP

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style
left-column

Alternative Products

Primary Antibodies

AB96233

Anti-LOXL2 antibody

BOND RX™ Validated

Immunocytochemistry/ Immunofluorescence - Anti-LOXL2 antibody (AB96233)

  • 4
  • 9
Primary Antibodies

AB202536

HRP Anti-LOXL2 antibody [EPR12733] - C-terminal

RabMAb|Recombinant

Western blot - HRP Anti-LOXL2 antibody [EPR12733] - C-terminal (AB202536)

  • 0
  • 0
Primary Antibodies

AB179810

Anti-LOXL2 antibody [EPR12733] - C-terminal

RabMAb|Recombinant|KO Validated

Western blot - Anti-LOXL2 antibody [EPR12733] - C-terminal (AB179810)

  • 4
  • 6
Primary Antibodies

AB213598

Anti-LOXL2 antibody [EPR12733] - BSA and Azide free

RabMAb|Recombinant|KO Validated

Western blot - Anti-LOXL2 antibody [EPR12733] - BSA and Azide free (AB213598)

  • 0
  • 0
Primary Antibodies

AB140833

Anti-LOXL2 antibody

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-LOXL2 antibody (AB140833)

  • 5
  • 3

Complementary Products

Assay Kits

AB275893

Human LOXL2 ELISA Kit

Recombinant|SimpleStep

Sandwich ELISA - Human LOXL2 ELISA Kit (AB275893)

  • 0
  • 0
Primary Antibodies

AB256451

Anti-EGFL7 antibody [EPR22603-113]

BOND RX™ Validated|RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-EGFL7 antibody [EPR22603-113] (AB256451)

  • 0
  • 0
Primary Antibodies

AB260043

Anti-Collagen I antibody [EPR22894-89]

RabMAb|Recombinant|Lab Essentials|20ul selling size

Western blot - Anti-Collagen I antibody [EPR22894-89] (AB260043)

  • 4
  • 3
Primary Antibodies

AB9485

Anti-GAPDH antibody - Loading Control

BOND RX™ Validated|Lab Essentials

Immunocytochemistry/ Immunofluorescence - Anti-GAPDH antibody - Loading Control (AB9485)

  • 5
  • 88
Primary Antibodies

AB92547

Anti-Vimentin antibody [EPR3776] - Cytoskeleton Marker

BOND RX™ Validated|KO Validated|RabMAb|Recombinant|Lab Essentials|20ul selling size|Advanced Validation

Multiplex immunohistochemistry - Anti-Vimentin antibody [EPR3776] - Cytoskeleton Marker (AB92547)

  • 5
  • 92
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/30", "IP-species-notes": "<p></p>", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>" } } }
style
left-column

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
style
left-column
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

Mediates the post-translational oxidative deamination of lysine residues on target proteins leading to the formation of deaminated lysine (allysine) (PubMed : 27735137). Acts as a transcription corepressor and specifically mediates deamination of trimethylated 'Lys-4' of histone H3 (H3K4me3), a specific tag for epigenetic transcriptional activation (PubMed : 27735137). Shows no activity against histone H3 when it is trimethylated on 'Lys-9' (H3K9me3) or 'Lys-27' (H3K27me3) or when 'Lys-4' is monomethylated (H3K4me1) or dimethylated (H3K4me2) (PubMed : 27735137). Also mediates deamination of methylated TAF10, a member of the transcription factor IID (TFIID) complex, which induces release of TAF10 from promoters, leading to inhibition of TFIID-dependent transcription (PubMed : 25959397). LOXL2-mediated deamination of TAF10 results in transcriptional repression of genes required for embryonic stem cell pluripotency including POU5F1/OCT4, NANOG, KLF4 and SOX2 (By similarity). Involved in epithelial to mesenchymal transition (EMT) via interaction with SNAI1 and participates in repression of E-cadherin CDH1, probably by mediating deamination of histone H3 (PubMed : 16096638, PubMed : 24414204, PubMed : 27735137). During EMT, involved with SNAI1 in negatively regulating pericentromeric heterochromatin transcription (PubMed : 24239292). SNAI1 recruits LOXL2 to pericentromeric regions to oxidize histone H3 and repress transcription which leads to release of heterochromatin component CBX5/HP1A, enabling chromatin reorganization and acquisition of mesenchymal traits (PubMed : 24239292). Interacts with the endoplasmic reticulum protein HSPA5 which activates the IRE1-XBP1 pathway of the unfolded protein response, leading to expression of several transcription factors involved in EMT and subsequent EMT induction (PubMed : 28332555). Involved in E-cadherin repression following hypoxia, a hallmark of EMT believed to amplify tumor aggressiveness, suggesting that it may play a role in tumor progression (PubMed : 20026874). When secreted into the extracellular matrix, promotes cross-linking of extracellular matrix proteins by mediating oxidative deamination of peptidyl lysine residues in precursors to fibrous collagen and elastin (PubMed : 20306300). Acts as a regulator of sprouting angiogenesis, probably via collagen IV scaffolding (PubMed : 21835952). Acts as a regulator of chondrocyte differentiation, probably by regulating expression of factors that control chondrocyte differentiation (By similarity).
See full target information LOXL2
style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com